Broker Center sponsored links

Abraxis gets FDA approval for chemotherapy drug

Wed Oct 17, 2007 8:35am EDT
 
Email | Print | | Reprints | Single Page
[-] Text [+]

Oct 17 (Reuters) - Abraxis BioScience Inc ABBI.O said U.S. health regulators approved its unit, Abraxis Pharmaceutical Products, to market chemotherapy drug Epirubicin hydrochloride injection in four dosage forms, two of which are new to market.

The company said the remaining two dosage forms are marketed by Pfizer Inc (PFE.N: Quote, Profile, Research) as Ellence.

Abraxis expects to launch Epirubicin in single dose vials in the fourth quarter. (Reporting by Ratul Ray Chaudhuri in Bangalore)

 

Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.

Have a correction to this article? Email the editors

Featured Broker sponsored link

Editor's Choice

Photo

A selection of our best photos from the past 24 hours.  View Slideshow 

Most Popular on Reuters